Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations
- PMID: 24105258
- DOI: 10.1038/clpt.2013.205
Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations
Abstract
Biomarkers are characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Amyloid measures become abnormal early in the Alzheimer's disease process and have only weak correlations with disease progression and cognitive decline; cerebrospinal fluid tau, brain atrophy, and reduced cortical metabolism correlate with cognitive measures and disease progression. Combinations of biomarkers have higher correlations and are better predictors of future decline than single biomarkers. Current biomarkers do not account for all of the variance in Alzheimer's disease; a more complete repertoire of biomarkers that more comprehensively assay the disease process is needed.
Similar articles
-
Post-translational modifications in Alzheimer's disease and the potential for new biomarkers.J Alzheimers Dis. 2014;41(2):345-64. doi: 10.3233/JAD-132312. J Alzheimers Dis. 2014. PMID: 24662105 Review.
-
Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer's disease.J Alzheimers Dis. 2013;33 Suppl 1:S329-47. doi: 10.3233/JAD-2012-129030. J Alzheimers Dis. 2013. PMID: 22735677 Review.
-
Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease.Psychol Med. 2010 Jan;40(1):135-45. doi: 10.1017/S0033291709991516. Epub 2009 Oct 29. Psychol Med. 2010. PMID: 19863841
-
Imaging and biomarkers for Alzheimer's disease.Maturitas. 2010 Feb;65(2):138-42. doi: 10.1016/j.maturitas.2009.12.006. Epub 2010 Jan 8. Maturitas. 2010. PMID: 20060241 Review.
-
Alzheimer's disease: biological aspects, therapeutic perspectives and diagnostic tools.J Phys Condens Matter. 2012 Jun 20;24(24):244102. doi: 10.1088/0953-8984/24/24/244102. Epub 2012 May 18. J Phys Condens Matter. 2012. PMID: 22595372 Review.
Cited by
-
A novel acetylcholinesterase inhibitor and calcium channel blocker SCR-1693 improves Aβ25-35-impaired mouse cognitive function.Psychopharmacology (Berl). 2016 Feb;233(4):599-613. doi: 10.1007/s00213-015-4133-5. Epub 2015 Nov 11. Psychopharmacology (Berl). 2016. PMID: 26554390
-
AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species.Curr Pharm Des. 2016;22(26):3950-70. doi: 10.2174/1381612822666160518141911. Curr Pharm Des. 2016. PMID: 27189600 Free PMC article. Review.
-
Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease.J Alzheimers Dis. 2015;45(3):709-19. doi: 10.3233/JAD-143099. J Alzheimers Dis. 2015. PMID: 25613100 Free PMC article.
-
Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer's Disease.Pharmaceuticals (Basel). 2020 Nov 26;13(12):424. doi: 10.3390/ph13120424. Pharmaceuticals (Basel). 2020. PMID: 33255969 Free PMC article. Review.
-
Predicting Progression to Mild Cognitive Impairment.Ann Neurol. 2019 Jan;85(1):155-160. doi: 10.1002/ana.25388. Epub 2019 Jan 7. Ann Neurol. 2019. PMID: 30521086 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical